Intensity of and adherence to lipid-lowering therapy as predictors of goal attainment and major adverse cardiovascular events in primary prevention
Authors' conclusion
In routine-care primary prevention, better adherence to LLT was associated with a lower risk of MACE across all treatment intensities.
Study context
- Population
- Adults newly initiating lipid-lowering therapy (LLT) for primary prevention of atherosclerotic cardiovascular disease (ASCVD), Stockholm, Sweden, 2017–2021median follow-up 2 years
- Participants
- 36,283 adults
- Exposure
- LLT adherence, intensity and adherence-adjusted intensity
- Outcome
- MACE and LDL-C goal attainment
Main finding
As reported in the abstract
MACE per 10% increase over 1 year
Hazard ratio (95% CI)
LLT adherence (+10%)
0.95(0.93–0.98)
LLT intensity (+10%)
0.93(0.86–1.00)
Adherence-adjusted intensity (+10%)
0.90(0.85–0.95)
Per 10% increase over 1 year, as printed
Observational data: associations, not effects.
Further findings
Major adverse cardiovascular events (MACE) and LDL-C goal attainment with good adherence (≥80%), by intensity
- Similar MACE risks and similar odds of LDL-C goal attainment with low-moderate and high-intensity LLT
Treatment discontinuation
- Associated with increased MACE risk
Benefit of good adherence by ASCVD risk
- Relative and absolute benefits greatest with very high ASCVD risk
Original publication
Intensity of and adherence to lipid-lowering therapy as predictors of goal attainment and major adverse cardiovascular events in primary prevention. Am Heart J. Published 16 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →